Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of zanubrutinib in B-cell malignancies
NL-OMON53996Phase 3Recruiting
- Sponsor
- BeiGene
- Start
- May 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of zanubrutinib in B-cell malignancy, mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM) and 3 more (2 arms), sponsored by BeiGene. Primary endpoints: Incidence of treatment-emergent adverse events and Incidence of serious adverse events. Started May 2022; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
B-cell malignancymantle cell lymphoma (MCL)Waldenström macroglobulinemia (WM)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NL-OMON53996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53996.